Extract
The World Health Organization (WHO) has listed moxifloxacin and linezolid among the preferred “group A” drugs in the treatment of multidrug-resistant (MDR)-tuberculosis (TB) [1]. Therapeutic drug monitoring (TDM) could potentially optimise MDR-TB therapy, since moxifloxacin and linezolid show large pharmacokinetic variability [1–4]. TDM of moxifloxacin focuses on identifying patients with low drug exposure who are at risk of treatment failure and acquired fluoroquinolone resistance [5, 6]. Alternatively, TDM of linezolid strives to reduce toxicity while ensuring an adequate drug exposure because of its narrow therapeutic index [1, 3, 7].
Abstract
Therapeutic drug monitoring using saliva as matrix is a suitable alternative for serum therapeutic drug monitoring of linezolid, but not for moxifloxacin due to a high variability in saliva-plasma ratios http://bit.ly/2NIYdz7
Footnotes
This study was registered at Clinicaltrials.gov with identifier number NCT03080012.
Conflict of interest: S.H.J. van den Elsen has nothing to disclose.
Conflict of interest: O.W. Akkerman has nothing to disclose.
Conflict of interest: E.M. Jongedijk has nothing to disclose.
Conflict of interest: M. Wessels has nothing to disclose.
Conflict of interest: S. Ghimire has nothing to disclose.
Conflict of interest: T.S. van der Werf has nothing to disclose.
Conflict of interest: D.J. Touw has nothing to disclose.
Conflict of interest: M.S. Bolhuis has nothing to disclose.
Conflict of interest: J-W.C. Alffenaar has nothing to disclose.
- Received September 25, 2019.
- Accepted January 10, 2020.
- Copyright ©ERS 2020